Palatin Technologies (PTN)
XASE:PTN
Want to see PTN full AI Analyst Report?
Top Page
Palatin Technologies
(NYSE MKT:PTN)
Select Model
Select Model
Rating:52Neutral
Price Target:
$20.50
▲(27.73% Upside)
Action:ReiteratedDate:04/15/26
The score is held back primarily by weak financial performance (large losses and persistent cash burn) and limited valuation support from negative earnings. Offsetting factors include improved near-term funding/runway and clear development timelines from the earnings call, plus a generally supportive price trend despite mixed momentum signals.
Positive Factors
High gross margins & low leverage
A ~99% gross margin reflects a licensing/royalty business mix that sustains high unit economics long-term, while minimal TTM debt (~$0.35M) preserves financial optionality. Together these structural features reduce near-term liquidity stress and support funding of R&D without heavy interest burden.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow indicates the company cannot self-fund development and will likely need additional financing ahead of pivotal value realization. Persistent cash burn elevates dilution risk and constrains strategic flexibility if capital markets tighten or warrant exercises fall short.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins & low leverage
A ~99% gross margin reflects a licensing/royalty business mix that sustains high unit economics long-term, while minimal TTM debt (~$0.35M) preserves financial optionality. Together these structural features reduce near-term liquidity stress and support funding of R&D without heavy interest burden.
Read all positive factors
Palatin Technologies (PTN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$38.61M
Dividend YieldN/A
Average Volume (3M)2.99K
Price to Earnings (P/E)―
Beta (1Y)-0.38
Revenue Growth271.10%
EPS Growth87.20%
CountryUS
Employees30
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.86
Shares Outstanding1,772,199
10 Day Avg. Volume2,746
30 Day Avg. Volume2,993
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.18
Enterprise Value/Market Cap14.79
Enterprise Value/Revenue63.70
Enterprise Value/Gross Profit64.19
Enterprise Value/Ebitda-59.70
Forecast
1Y Price Target
$50.00Price Target Upside211.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.45
Revenue Forecast (FY)$9.68M
Palatin Technologies Business Overview & Revenue Model
Company Description
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for ...
How the Company Makes Money
Palatin historically has generated revenue primarily through collaboration, licensing, and commercialization-related arrangements around its drug candidates, rather than through broad-based product sales. Key revenue sources have included: (1) lic...
Palatin Technologies Earnings Call Summary
Earnings Call Date:Feb 17, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:May 19, 2026
Earnings Call Sentiment Positive
The call highlighted substantial strategic and financial progress: a successful $18.2M public offering (net $16.9M), regained NYSE American listing, a $14.5M cash balance with a runway beyond March 31, 2027, and clear IND/Phase I timelines for two MC4R programs with sufficient cash to execute Phase I. Offsetting these positives are materially higher operating expenses and a larger net loss versus the prior year, minimal current commercial revenue, a decline in other income, and remaining uncertainties around warrant exercises and clinical differentiation. On balance, the financing and clear development milestones materially de-risk near-term execution, while the company still faces typical biotech development and competitive risks.Positive Updates
Successful Financing and Strengthened Balance Sheet
Completed an upsized underwritten public offering on November 12, 2025 with gross proceeds of $18.2M and net proceeds of approximately $16.9M; offering included ~2.8M shares/prefunded warrants and Series J/K warrants. The financings restored NYSE American compliance and resumed trading under symbol PTN.
Negative Updates
Increased Operating Expenses
Total operating expenses rose to $7.4M for the quarter ended December 31, 2025 versus $2.6M in the prior-year period — an increase of approximately 185% year-over-year — driven by higher investment in MC4R obesity programs, increased compensation and professional fees, and the absence of a prior-year gain on the sale of Vyleesi.
Read all updates
Q2-2026 Updates
Positive
Negative
Successful Financing and Strengthened Balance Sheet
Completed an upsized underwritten public offering on November 12, 2025 with gross proceeds of $18.2M and net proceeds of approximately $16.9M; offering included ~2.8M shares/prefunded warrants and Series J/K warrants. The financings restored NYSE American compliance and resumed trading under symbol PTN.
Read all positive updates
Company Guidance
Management provided program and financial guidance to advance its melanocortin‑4 receptor obesity portfolio with IND submission and initiation of a Phase I SAD/MAD for the oral small molecule PL‑7737 in H1 calendar 2026 (Phase I readout by year‑end 2026), a once‑weekly peptide IND planned in H2 2026 (peptide Phase I readout in H1 2027) and subsequent HO and Prader‑Willi Phase II/II‑III trials not to start before mid‑2027; financially, Palatin closed an upsized $18.2M public offering on Nov 12, 2025 (≈2.8M shares/prefunded warrants at $6.50, net proceeds ≈$16.9M, Series J warrants exercisable at $6.50 and expiring the earlier of 18 months or 31 days after FDA IND acceptance, Series K warrants exercisable at $8.125 with a 5‑year term), noted potential additional proceeds up to $18.2M if Series J exercised, received ≈$3.8M upfront from the PL9643 sublicensing (non‑cash debt cancellation to be recognized as license revenue in the quarter ending Mar 31, 2026), reported Q2 FY2026 revenue of $116k, total operating expenses of $7.4M (vs $2.6M prior year), other income net of ~$65k, net cash used in operations of $4.8M, net loss of $7.3M or $2.86/share (vs $2.4M or $5.92/share prior year), cash and cash equivalents of $14.5M as of Dec 31, 2025 (vs $1.3M at Sep 30, 2025 and $2.6M at Jun 30, 2025) with a cash runway expected to extend beyond the quarter ending Mar 31, 2027, and management noted >$2M of one‑time items in a prior quarter and expects roughly $2.5M lower OpEx going forward.Palatin Technologies Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
14
Very Negative
| Breakdown | TTM | Jun 2025 | Sep 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.96M | 0.00 | 4.49M | 4.85M | 1.47M | -188.60K |
| Gross Profit | 8.90M | -258.92K | 4.39M | 4.44M | 1.25M | -336.44K |
| EBITDA | -9.56M | -17.03M | -29.38M | -28.40M | -35.68M | -33.52M |
| Net Income | -9.63M | -17.31M | -29.74M | -24.04M | -36.20M | -33.57M |
Balance Sheet | ||||||
| Total Assets | 17.93M | 3.27M | 10.74M | 17.94M | 36.07M | 67.30M |
| Cash, Cash Equivalents and Short-Term Investments | 14.48M | 2.56M | 9.53M | 10.98M | 29.94M | 60.10M |
| Total Debt | 348.79K | 163.78K | 590.34K | 1.05M | 1.15M | 1.25M |
| Total Liabilities | 6.46M | 8.04M | 10.85M | 19.92M | 19.80M | 17.65M |
| Stockholders Equity | 11.47M | -4.78M | -111.50K | -1.98M | 16.27M | 49.65M |
Cash Flow | ||||||
| Free Cash Flow | -15.88M | -21.31M | -31.50M | -28.85M | -30.18M | -22.65M |
| Operating Cash Flow | -15.87M | -21.31M | -31.46M | -28.42M | -29.92M | -22.65M |
| Investing Cash Flow | 617.18K | 3.13M | 12.45M | -3.43M | -261.37K | -5.72K |
| Financing Cash Flow | 26.31M | 11.21M | 20.55M | 9.90M | 18.36K | -93.64K |
Palatin Technologies Technical Analysis
Positive
16.05
Price Trends
20.15
Positive
19.36
Positive
14.00
Positive
Market Momentum
0.14
Negative
60.33
Neutral
91.52
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PTN, the sentiment is Positive. The current price of 16.05 is below the 20-day moving average (MA) of 19.57, below the 50-day MA of 20.15, and above the 200-day MA of 14.00, indicating a bullish trend. The MACD of 0.14 indicates Negative momentum. The RSI at 60.33 is Neutral, neither overbought nor oversold. The STOCH value of 91.52 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PTN.
Palatin Technologies Risk Analysis
Palatin Technologies disclosed 48 risk factors in its most recent earnings report. Palatin Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Palatin Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $38.61M | -0.51 | -5515.09% | ― | 271.10% | 87.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $15.33M | -1.29 | -107.58% | ― | ― | 83.95% | |
51 Neutral | $9.31M | -1.12 | -71.27% | ― | -72.15% | -223.62% | |
47 Neutral | $9.43M | -0.31 | -97.58% | ― | -46.88% | 34.83% | |
46 Neutral | $72.54M | ― | -71.26% | ― | 185.71% | 79.03% | |
44 Neutral | $6.62M | -0.82 | -420.31% | ― | 1.70% | -111.67% |
* Healthcare Sector Average
PTN
Palatin Technologies
22.50
10.95
94.81%
IBIO
Ibio
2.06
1.21
143.21%
PHIO
Phio Pharmaceuticals
1.29
-1.54
-54.42%
BRTX
BioRestorative Therapies
0.26
-1.45
-84.62%
ADXN
Addex Therapeutics
6.72
-0.03
-0.44%
BOLT
Bolt Biotherapeutics
4.73
-2.09
-30.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.